Clinical Trial

Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 30, 2024 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this single-arm, prospective clinical trial is to evaluate the safety and efficacy of neoadjuvant therapy combining sintilimab with stereotactic body radiation therapy (SBRT) in patients with resectable hepatocellular carcinoma (HCC) with branch portal vein tumor thrombus. The main questions it aims to answer are: 1. Is the combination of sintilimab and SBRT safe as neoadjuvant therapy? 2. How effective is this combination in treating resectable HCC with branch PVTT? Participants will be given a combination treatment of sintilimab and SBRT. Researchers will monitor their health conditions to assess the safety and effectiveness of this treatment protocol.
Trial Details
NCT Number NCT06664996
Lead Sponsor West China Hospital
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 33 participants
Start Date 2024-10-15
Primary Completion 2025-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2024-10-30